Medical cannabis may be cost-effective for MS spasticity and Dravet syndrome, but evidence is limited
A systematic review of 12 economic evaluations found that nabiximols appears cost-effective for MS spasticity in Europe and CBD for Dravet syndrome in Canada, though cost-effectiveness varied widely depending on setting and indication.
Quick Facts
What This Study Found
Twelve cost-utility analyses were identified across MS (n=8), pediatric epilepsies (n=2), and chronic pain (n=2). Incremental cost-effectiveness ratios ranged from cost-saving to over $451,800 per quality-adjusted life-year. Nabiximols was consistently cost-effective for MS spasticity in European settings. CBD was cost-effective for Dravet syndrome in Canada but not for Lennox-Gastaut syndrome in the US.
Key Numbers
12 cost-utility analyses; 8 for MS, 2 for epilepsy, 2 for chronic pain; cost-effectiveness ratios ranged from cost-saving to >$451,800/QALY; median CHEERS quality 83% (range 70-100%)
How They Did This
Systematic search of seven databases for economic evaluations of medicinal cannabis published through September 2020. Quality assessed using the CHEERS checklist. Data grouped by medical condition and reported narratively.
Why This Research Matters
As medicinal cannabis is often expensive compared to illicit supply, understanding its cost-effectiveness is essential for healthcare systems making coverage and formulary decisions.
The Bigger Picture
The wide range of cost-effectiveness ratios highlights that medicinal cannabis value depends heavily on the specific product, indication, and healthcare system. Blanket statements about cost-effectiveness are not supported.
What This Study Doesn't Tell Us
Only 12 studies identified, reflecting the nascent state of cannabis health economics. Most studies focused on MS. Limited geographic diversity. Economic models depend on clinical trial data that may not reflect real-world effectiveness.
Questions This Raises
- ?Would cost-effectiveness improve as medicinal cannabis production scales and prices decrease?
- ?Are there conditions beyond MS and epilepsy where cannabis-based medicines would be cost-effective?
Trust & Context
- Key Stat:
- Cost-effectiveness ratios ranged from cost-saving to >$451,800 per QALY
- Evidence Grade:
- Systematic review with good-quality included studies, but the small number and limited scope of conditions reviewed constrain the conclusions.
- Study Age:
- Published in 2021 reviewing studies through September 2020.
- Original Title:
- Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations.
- Published In:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(10), 1520-1530 (2021)
- Authors:
- Erku, Daniel(2), Shrestha, Shakti, Scuffham, Paul(2)
- Database ID:
- RTHC-03120
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Is medical cannabis a good value for healthcare systems?
It depends. Nabiximols for MS spasticity appears cost-effective in multiple European settings. CBD for Dravet syndrome was cost-effective in Canada. But for other conditions and settings, the evidence is too limited to draw conclusions.
Why is the cost range so wide?
Different products (nabiximols, CBD, other formulations), different conditions, different healthcare systems, and different comparison treatments all affect cost-effectiveness calculations. There is no single answer for all of medical cannabis.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03120APA
Erku, Daniel; Shrestha, Shakti; Scuffham, Paul. (2021). Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(10), 1520-1530. https://doi.org/10.1016/j.jval.2021.04.1276
MLA
Erku, Daniel, et al. "Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations.." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2021. https://doi.org/10.1016/j.jval.2021.04.1276
RethinkTHC
RethinkTHC Research Database. "Cost-Effectiveness of Medicinal Cannabis for Management of R..." RTHC-03120. Retrieved from https://rethinkthc.com/research/erku-2021-costeffectiveness-of-medicinal-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.